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The gut microbiome is impacted by environmental exposures and has been implicated in many physical and
mental health conditions, including anxiety disorders, affective disorders, and trauma- and stressor-related disorders such as posttraumatic stress disorder (PTSD). United States (US) military Veterans are a unique population
in that their military-related exposures can have consequences for both physical and mental health, but the gut
microbiome of this population has been understudied. In this publication, we describe exposures, health conditions, and medication use of Veterans in the US Veteran Microbiome Project (US-VMP) and examine the associations between these characteristics and the gut microbiota. This cohort included 331 US Veterans seeking
healthcare with the Veterans Health Administration who were 83% male with an average (SD) age of
47.6  13.4 years. The cohort displayed a high prevalence of PTSD (49.8%) and history of traumatic brain injuries
(76.1%), and high current use of prescription medications (74.9%) to treat various acute and chronic conditions.
We observed signiﬁcant associations between the gut microbiota composition and gastroenteritis, peripheral
vascular disease (PVD), bipolar disorders, symptoms of severe depression based on the Beck Depression Inventory,
stimulant and opioid use disorders, beta-blockers, serotonin and norepinephrine reuptake inhibitor antidepressants, diabetes medications, and proton pump inhibitors. Many of the Veteran characteristics examined were
associated with altered relative abundances of speciﬁc taxa. We found that PVD and cardiovascular disease were
associated with lower microbiota diversity in the gut (i.e., α-diversity), while supplemental vitamin use was
associated with higher α-diversity. Our study contributes novel insights as to whether the unique exposures of
Veterans in this cohort correlate with gut microbiota characteristics and, in line with previous ﬁndings with other
population-level studies of the microbiome, conﬁrms associations between numerous health conditions and
medications with the gut microbiome.
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a unique opportunity to examine the associations between the gut
microbiota and various exposures among Veterans. In this study, we
aimed to quantify the strength and nature of associations between Veteran characteristics, health conditions, and medications with the participants’ gut microbiota.

1. Introduction
United States (US) military Veterans have exposures that can be
different from those experienced by civilians. An unfortunate outcome of
war and conﬂict can be disruptions to physical and mental health, which
can result in changes to physiology and lifestyle that sometimes persist
for the duration of Veterans’ lives. Many US Veterans have access to
healthcare through the Veterans Health Administration (VHA). Electronic medical records (EMRs) within the VHA often contain comprehensive historical information including combat exposures, medical
procedures, health conditions, and medication prescriptions. This information can provide valuable insight into health outcomes.
In recent years, evidence has come to light that environmental factors,
health conditions, and medications may impact the gut microbiota (Cenit
et al., 2017; Dinan and Cryan, 2017; Maier et al., 2018). There is also
evidence that the gut microbiota may be associated with mental health
disorders, such as depression, bipolar disorder, and schizophrenia
(Cheung et al., 2019; Nguyen et al., 2018; Fond et al., 2020). Converging
lines of evidence suggest that the connection between the gut microbiota
and mental health disorders involves the immune system, speciﬁcally
inﬂammatory pathways (Lowry et al., 2016). The gut microbiota has also
been implicated in numerous inﬂammatory-related health conditions,
including obesity and diabetes mellitus (Turnbaugh et al., 2009a; Sanna
et al., 2019; Maruvada et al., 2017). The gut microbiota may also mediate
the beneﬁts of certain medications, such as metformin use for managing
blood glucose in diabetes (Forslund et al., 2015; Jackson et al., 2018).
Recent population-level studies have helped to quantify the relative
importance of different correlates of the gut microbiota (Jackson et al.,
2018; Falony et al., 2016), but it is unknown how well these results
translate to a US Veteran population seeking care at the VHA, with
unique environmental exposures, complex health conditions, and a high
prevalence of medication use.
US Veteran Microbiome Project (US-VMP) investigators have been
collecting microbiome samples from Veterans since 2015 (Brenner et al.,
2018). Participants are recruited among those who are eligible to receive
care within the Veterans Affairs (VA) Eastern Colorado Health Care
System (ECHCS). The combination of microbiome and EMR data present

2. Materials and methods
2.1. Study design
This was a cross-sectional observational study of US military
Veterans.
2.2. Study participants
The US-VMP was launched over six years ago in order to longitudinally assess the skin, oral, and fecal microbiomes of US Veterans, as well
as collect validated measures of physical and mental health (Brenner
et al., 2018). Participants were Veterans eligible to receive care within
the ECHCS. This study includes data from all of the N ¼ 331 Veterans
who entered the study between June 2016 and November 2018,
completed baseline measures, and provided a fecal sample that was
successfully sequenced (N ¼ 13 were excluded due to poor sequencing
depth of the fecal samples).
2.3. Data collection
Data collection for the US-VMP has been previously described in
detail, including the microbiome sample collection (Brenner et al., 2018).
Information was collected during in-person visits and from the VA EMR.
Height and weight were collected for calculation of body mass index
(BMI). Mental health diagnoses (lifetime bipolar disorders, anxiety disorders and posttraumatic stress disorder [PTSD]) and current substance
use disorders were identiﬁed via the Structured Clinical Interview for the
Diagnostics and Statistical Manual of Mental Disorders (SCID) Version 5
(DSM-5) Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-5-I/P W/PSY SCREEN) (First et al., 2016). The
2
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inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors
(SNRIs)), insomnia medications, and other psychiatric medications; 2)
cardiovascular medications, including statins, angiotensin-converting
enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs),
blood pressure medications, beta-blockers, antithrombotics, and other
cardiovascular medications/supplements; 3) pain medications, including
nonsteroidal anti-inﬂammatory drugs (NSAIDs), opioids, muscle relaxers, and non-opioid analgesics; 4) gastrointestinal (GI) medications,
including proton pump inhibitors (PPIs), laxatives, and other GI medications; 5) supplemental vitamins, including vitamin D; 6) neurologic
seizure medications; 7) pulmonary medications, including bronchodilators; 8) endocrine medications, including diabetes and thyroid medications; and, 9) urogenital medications, including those for sexual function.
Speciﬁc medications analyzed included the following, which were the
most commonly prescribed: trazadone, bupropion, atorvastatin, lisinopril, prazosin, gabapentin, metformin, levothyroxine, sildenaﬁl, albuterol, omeprazole, and cholecalciferol.

SCID-5 is a comprehensive semi-structured clinical interview that is a
reliable and valid means to acquire information regarding psychiatric
disorders (Diagnostic and Statistical Manual of Mental Disorders, 2013).
Presence of bipolar disorders was determined by a lifetime diagnosis of
bipolar I, bipolar II, or other speciﬁed bipolar disorder. Presence of
anxiety disorders was determined by a lifetime diagnosis of panic disorder, agoraphobia, social anxiety disorder, speciﬁc phobia, generalized
anxiety disorder, separation anxiety disorder, other speciﬁed anxiety
disorder, and anxiety disorder due to another medical condition. PTSD
diagnosis required all necessary criteria including exposure to a traumatic event and sufﬁcient symptoms. Presence of substance abuse was
determined by a current diagnosis of abuse of cannabis, hallucinogens,
inhalants, opioids, sedatives, hypnotics, anxiolytics, stimulants, or tobacco. Presence of alcohol use disorder was determined by a current
diagnosis of alcohol use disorder. Depressive symptoms were identiﬁed
by responses to the Beck Depression Inventory (BDI) (Beck et al., 1961).
Additional measures included the Physical Health Composite Score (PCS)
from the 36-Item Short Form Health Survey (SF-36) (Brazier et al., 1992)
and the Insomnia Severity Index (ISI) (Morin, 1993). History of traumatic
brain injury (TBI) was determined by the Ohio State University Traumatic Brain Injury Identiﬁcation Method (OSU TBI-ID) (Bogner and
Corrigan, 2009). For the individuals with data missing (<5%) from some
of these surveys, single imputation was performed using fully conditional
speciﬁcation methods via PROC MI in SAS v9.4 (SAS Institute, Cary, NC,
USA).
Health conditions were identiﬁed via National Health Interview
Survey of Chronic Conditions (Kovar and Poe, 1985). In addition to
querying the VA EMR (vital status, inpatient hospitalizations, outpatient
clinic visits, and fee basis ﬁles) diagnoses of the following were identiﬁed
using International Classiﬁcation of Diseases, Ninth and Tenth Revision
(ICD-9 and ICD-10) codes: cancer; congestive heart failure (CHF); peripheral vascular disease (PVD); cardiovascular disease (CVD); diabetes;
liver disease; renal disease; chronic pulmonary disease (CPD); and
gastroenteritis (ICD-9 and ICD-10 codes are lised in Appendix A;
Table A1). Diagnoses were included in analyses if they were charted
within one year prior to each participant's consent date in order to ensure
that they were relatively current, and that the detection of health conditions was not overly biased towards older, long-term users of VA care.
Additionally, a one year timeframe is often used for comorbidity
assessment from EMRs (Casey et al., 2016; Lund et al., 2021). Medications were extracted from the VA EMR pharmacy prescriptions and reﬁll
records, including all medications with adequate supply to cover the two
weeks preceding the fecal microbiota sample collection. Topical medications were excluded.

2.5. Microbiome sample processing
Sample DNA was extracted as previously described from fecal samples using the PowerSoil DNA extraction kit (Cat. No. 12955–4, Qiagen,
Valencia, CA, USA). Marker genes in isolated DNA were PCR-ampliﬁed
using GoTaq Master Mix (Cat. No. M5133, Promega, Madison, WI,
USA) as described in Caporaso et al. (2012) PCR products were cleaned
and normalized using the SequalPrep Normalization Kit (Cat. No.
A1051001, ThermoFisher, Waltham, MA, USA) following manufacturer's
instructions. The normalized amplicon pool was sequenced on an Illumina MiSeq. All library preparation and sequencing were conducted at
the University of Colorado Boulder BioFrontiers Next-Gen Sequencing
core facility.
Sequencing data were processed using the Quantitative Insights Into
Microbial Ecology program (QIIME2 v. 2019.10 (Bolyen et al., 2019)).
The Deblur (Amir et al., 2017a) algorithm was used to denoise demultiplexed sequences. SATe-enabled phylogenetic placement (SEPP (Janssen et al., 2018)) analysis was performed to remove sequences that were
not 75% similar to any record in the tree. Quality-ﬁltered sequences were
assigned taxonomic classiﬁcation based on the silva_128 database (Quast
et al., 2013). Samples that were shipped to the research facility and had
taxa that are known to “bloom” during shipping were removed as previously described by Amir et al. (2017b). Additionally, taxa that have
been identiﬁed to “bloom” with increased time spent at room temperature were also considered for removal (Bokulich et al., 2019). Details of
how we performed and assessed “deblooming” analysis can be found in
the supplemental materials (Appendix B; Fig. B1; Table B1) (Amir et al.,
2017b). For α- and β-diversity and taxonomic evaluations, samples were
rareﬁed to a level of 2535 sequences per sample. The α-diversity metrics
assessed were observed species, Shannon diversity, and Faith's phylogenetic diversity (PD). These measures capture different aspects of the
microbiota diversity of each sample: observed species represents the
richness of different types of microbiota detected, Shannon diversity
gives equal weight to evenness and richness, and PD takes into account
phylogenetic relatedness. The β-diversity metrics assessed were unweighted and weighted UniFrac. Jaccard and Bray-Curtis distance metrics were used to infer functional information (MetaCyc pathways (Caspi
et al., 2014)) using Picrust2 v2.3.0-b (Douglas et al., 2019). These metrics
capture the diversity across samples (differences in the microbiota between samples). Weighted UniFrac and Bray-Curtis are quantitative
measures (i.e., take into account abundance of the microbes/functional
pathways present). Unweighted UniFrac and Jaccard are qualitative (i.e.,
take into account only presence/absence of the microbes/functional
pathways).

2.4. Classiﬁcation of exposures into four groups of predictors
We grouped the potential correlates of the gut microbiota into four
broad categories of predictors: 1) demographics; 2) health conditions and
metrics; 3) medication classes; and, 4) speciﬁc medications. Demographics included age, sex, ethnicity (Hispanic versus non-Hispanic),
self-described race (Caucasian, African American, or Other), history of
homelessness, history of combat exposure, and deployment history.
Health conditions and metrics included BMI, severe depressive symptoms
as measured by the BDI, lifetime bipolar disorders, lifetime anxiety disorders, lifetime PTSD, history of TBI, current alcohol use disorder, and
current substance use disorders (i.e., cannabis, opioids, and stimulants),
SF-36 PCS, ISI, cancer, CHF, PVD, CVD, diabetes, liver disease, renal
disease, CPD, and gastroenteritis.
We focused our analyses on medications reported for at least 25 individuals in the cohort. Using the Epocrates drug classiﬁcation system,
(Epocrates) medications were grouped broadly by type of condition
typically treated (though many medications are used for numerous
conditions) and then into classes of medications, each of which include
numerous speciﬁc types of medications: 1) psychiatric medications,
including antidepressants (atypicals, selective serotonin reuptake

2.6. Statistical analyses
We used Pearson's correlation coefﬁcient to assess the strength of
3
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permutational multivariate analysis of variance (PERMANOVA) using
the vegan package (Oksanen et al., 2018) and a stepwise model building
tool for constrained ordination methods (ordistep) (Douglas et al., 2019)
based on adjusted R2 using the UniFrac distance metrics. We applied the
same methods to the inferred gut microbiota MetaCyc functional pathways (Caspi et al., 2014), quantifying the pathway abundance using
Jaccard and Bray-Curtis distance metrics. In order to determine the
strongest correlates of the three measures of the gut microbiota α-diversity, we used a similar model building tool for linear regression
models, LEAPS (Miller, 1984). Analysis of Compositions of Microbiomes
(ANCOM) (Mandal et al., 2015) was used to assess whether any gut
microbiota taxa were differentially abundant with these predictors. For
taxonomic analyses, we adjusted for multiple testing using a
Benjamini-Hochberg (Benjamini and Hochberg, 1995) False Discovery
Rate (FDR) with a two-tailed statistical signiﬁcance threshold of 0.05,
which was likewise used for two-tailed p-values in analyses of α- and
β-diversity. Analyses were performed with QIIME2 v. 2019.10 (Bolyen
et al., 2019), the open source statistical package R v.3.5.1 (R Core Team,
2018) and python v3.6.7 (Van Rossum and Drake, 2009).

Table 1
Characteristics of the US-VMP cohort.
N

331

Demographics
Age (years)
Male sex
Hispanic ethnicity
Race

47.6 (13.4)
275 (83.1)
53 (16.0)

Caucasian
African American
Other
Number of periods of homelessness
Periods of homelessness
Never
1-2 times
3þ times
Deployment history
Never
1-2 times
3þ times
Health Conditions and Metrics
Body mass index (kg/m2)
BMI category
Underweight
Normal weight
Overweight
Obese
Severe depressive symptoms (BDI)
Bipolar disorders (lifetime)
Anxiety disorders (lifetime)
Posttraumatic stress disorder (lifetime)
Number of traumatic brain injuries
Prevalence of TBI in cohort
SF-36 Physical Health Composite score
Insomnia Severity Index
Prevalence of clinical insomnia
Cancer
Congestive heart failure
Peripheral vascular disease
Cardiovascular disease
Diabetes
Liver disease
Renal disease
Chronic pulmonary disease
Gastroenteritis
Alcohol use disorder (current)
Substance use disorder (current)
Cannabis
Opioids
Stimulants
Medications
Current VA medication

62 (18.7)
218 (65.9)
51 (15.4)
1.6 (6.1)
192 (58.0)
76 (23.0)
63 (19.0)
100 (30.2)
144 (43.5)
87 (26.3)
29.0 (6.1)
1 (0.3)
90 (27.2)
114 (34.4)
126 (38.1)
60 (18.1)
17 (5.1)
38 (11.5)
165 (49.8)
1.9 (1.8)
76.1
45.2 (10.2)
11.9 (7.6)
35
18 (5.4)
8 (2.4)
9 (2.7)
17 (5.1)
52 (15.7)
28 (8.5)
18 (5.4)
49 (14.8)
41 (12.4)
40 (12.1)
25 (7.6)
20 (6.0)
5 (1.5)
20 (6.0)

3. Results
Among the 331 Veterans in the US-VMP cohort, over two-thirds
experienced at least one deployment, and many of the Veterans (42%)
reported at least one period of homelessness (Table 1). There was high
prevalence of health conditions with: 1) over 35% having self-reported
clinical insomnia; 2) almost 50% having a lifetime diagnosis of PTSD;
and, 3) over three-quarters reporting at least one TBI of any severity
(mild, moderate or severe). Approximately 12% of Veterans reported
current alcohol use disorder and 7.6% reported some type of other current substance use disorder, such as cannabis, opioids, or stimulants.
3.1. The majority of veterans had multiple medication prescriptions
Three-quarters of the US-VMP cohort had at least one current medication prescription noted within the EMR. These individuals had an
average of six prescriptions for unique medications (median ¼ 4,
IQR ¼ 2–8). Psychiatric medications were the most prevalent class, with
antidepressants being the most common sub-class (Table 2); 137 individuals (41.4% of the overall cohort) had an active prescription for
antidepressants, most commonly atypical antidepressants (speciﬁcally,
trazadone or bupropion), SSRIs, or SNRIs. CVD medications were also
common (38.1% of the cohort), such as statins, ACEIs/ARBs, betablockers, and other blood pressure medications. Almost one-third
(32.6%) of the cohort had some type of pain medication, with 13%
taking prescription opioids.
We examined the correlation between health conditions and medications (Fig. 1). The overall health metric of the SF-36 PCS correlated
negatively with prescription medications (r ¼ 0.25), as would be expected. The most strongly correlated disease-medication pair was diabetes and metformin (r ¼ 0.58). Many individuals with diabetes were
also prescribed CVD medications, particularly statins (r ¼ 0.43). CHF
correlated highly with beta-blockers (r ¼ 0.47), and CPD with albuterol
(r ¼ 0.43).

248 (74.9)

Footnote. Numbers are presented as mean (SD) for continuous measures and
prevalence (%) for categorical data. Severity of depressive symptoms was
determined from the BDI. Bipolar disorders (lifetime diagnosis of bipolar I, bipolar II, or other speciﬁed bipolar disorder), anxiety disorders (lifetime diagnosis
of panic disorder, agoraphobia, social anxiety disorder, speciﬁc phobia, generalized anxiety disorder, separation anxiety disorder, other speciﬁed anxiety
disorder, or anxiety disorder due to another medical condition), posttraumatic
stress disorder, current alcohol use disorder, and current substance use disorders
(i.e., cannabis, opioids, and stimulants) were determined from the SCID-5-I/P W/
PSY SCREEN. TBI history was determined by the OSU-TBI-ID. Abbreviations:
BDI, Beck Depression Inventory; BMI, body mass index; OSU-TBI-ID, The Ohio
State University Traumatic Brain Injury Identiﬁcation Method; SCID-5-I/P W/
PSY SCREEN, Structured Clinical Interview for the Diagnostic and Statistical
Manual for Mental Health Disorders Version 5 (DSM-5) Axis I Disorders,
Research Version, Patient Edition with Psychotic Screen; SD, standard deviation;
SF-36, 36-Item Short Form Health Survey; TBI, traumatic brain injury.

3.1.1. The gut microbiota taxonomic compositions were correlated with
numerous health conditions and medications
We evaluated associations between the overall gut microbiota
composition, Veteran characteristics, and medications using two phylogenetic measures of composition that take into account the types of
microbiota present or absent in a sample (unweighted UniFrac) and the
relative abundance of the microbiota present (weighted UniFrac) (Lozupone et al., 2011). We identiﬁed the strongest correlates of the gut
microbiome composition by examining each exposure independently
using PERMANOVA (Fig. 2) and also through a stepwise constrained
ordination approach (Table 3, Fig. 3) that identiﬁes important sets of

association between the health conditions and medications. We assessed
the amount of variation in the gut microbiota composition explained by
the four groups of predictors (described in detail above) using distancebased redundancy analyses of the unweighted and weighted UniFrac(Lozupone et al., 2011) distance metrics. In order to determine the
strongest correlates of the gut microbiota composition, we used
4
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correlated most strongly with the weighted UniFrac distance metric
(Table 3, Fig. 3B). Among the health conditions and metrics, we found
that PVD (P ¼ 0.02), bipolar disorders (P ¼ 0.04), stimulant use disorder
(P ¼ 0.05), gastroenteritis (P ¼ 0.05), and severe depressive symptoms
(based on BDI; P ¼ 0.05) correlated with unweighted UniFrac (Table 3,
Fig. 3A). Bipolar (P ¼ 0.03) and stimulant use (P ¼ 0.02) disorders also
correlated signiﬁcantly with weighted UniFrac, as did opioid use disorder
(P ¼ 0.05) (Table 3, Fig. 3B). Among medication classes and speciﬁc
medications, beta-blockers (P ¼ 0.01), SNRI antidepressants (P ¼ 0.01),
and diabetes medications (P ¼ 0.03) correlated with unweighted UniFrac
(Table 3, Fig. 3A). Other GI medications (P ¼ 0.01), PPIs (P ¼ 0.05) and
omeprazole, which is a PPI (P ¼ 0.03), correlated with weighted UniFrac
(Table 3, Fig. 3B). We were able to identify speciﬁc taxa that differed
between groups for many of the Veteran demographic characteristics and
health metrics/conditions examined, including deployments, severe
depressive symptoms, bipolar disorders, anxiety disorders, clinical
insomnia, CHF, PVD, diabetes, gastroenteritis, opioid use disorder, and
stimulant use disorder (Fig. 4). Likewise, both classes of and speciﬁc
medications were associated with signiﬁcant shifts in some taxa,
including diabetes medications, SNRI antidepressants, statins, betablockers, muscle relaxers, PPIs, other GI medications (which included
digestive enzymes and heart burn medications, most commonly ranitidine), other supplemental vitamins, seizure medications, bronchodilators, metformin, omeprazole, and gabapentin.

Table 2
Medication prescriptions among the US-VMP cohort.
Medication class

Speciﬁc medication

N (%)
331

Psychiatric
Antidepressants
Atypical antidepressants
Trazodone
Bupropion
SSRI antidepressants
SNRI antidepressants
Insomnia
Other
CVD
Statins
Atorvastatin
ACEI/ARBs
Lisinopril
Blood pressure
Prazosin
Beta-blockers
Antithrombotics
Other
Pain management
NSAIDs
Opioids
Muscle relaxers
Non-opioid analgesic
Gastrointestinal (GI)
PPI
Omeprazole
Laxatives
GI - Other
Supplemental vitamins
Vitamin D
Cholecalciferol
Neurologic

Vitamins - Other
Seizures
Gabapentin

Pulmonary
Bronchodilators
Albuterol
Endocrine
Diabetes
Thyroid

Metformin
Levothyroxine

Urology
Sexual function
Other medications

Sildenaﬁl

152 (45.9)
137 (41.4)
72 (21.8)
40 (12.1)
29 (8.8)
58 (17.5)
37 (11.2)
25 (7.6)
33 (10)
126 (38.1)
56 (16.9)
40 (12.1)
44 (13.3)
25 (7.6)
54 (16.3)
26 (7.9)
34 (10.3)
29 (8.8)
41 (12.4)
108 (32.6)
43 (13)
43 (13)
39 (11.8)
30 (9.1)
83 (25.1)
50 (15.1)
38 (11.5)
30 (9.1)
27 (8.2)
83 (25.1)
54 (16.3)
44 (13.3)
50 (15.1)
59 (17.8)
30 (9.1)
54 (16.3)
48 (14.5)
30 (9.1)
52 (15.7)
26 (7.9)
24 (7.3)
50 (15.1)
28 (8.5)
79 (23.9)

3.1.2. The overall gut microbiota functional composition was correlated with
numerous health conditions and medications
We used a similar approach in order to identify the strongest correlates of the gut microbiome functional pathways (Table 4; Fig. 5), using
Jaccard and Bray-Curtis distance metrics based on functional information
inferred using Phylogentic investigation of Communities by reconstruction of unobserved states v2 (PiCrust2) (Douglas et al., 2020), which are
comparable to unweighted and weighted UniFrac, respectively. Sex
(P ¼ 0.002), CHF (P ¼ 0.03), muscle relaxers (P ¼ 0.01), and omeprazole
(P ¼ 0.02) (a PPI) were associated with differences in the types of
functional pathways present or absent (Jaccard distance metric). Sex
(P ¼ 0.002) and omeprazole (P ¼ 0.006) were likewise associated with
the abundance of functional pathways (Bray-Curtis distance metric), as
were race (P ¼ 0.04), SF-36 PCS (P ¼ 0.02), and other supplemental
vitamins (P ¼ 0.002). As shown in Fig. 5, samples from individuals with
CHF or taking muscle relaxers are clustered together with functions
related to the TCA cycle.

Footnote: Medications ordered for Veterans covering the period within two
weeks of their gut microbiota sample collection. Medications are grouped into
broad disease categories that reﬂect their primary use, and then further grouped
into general classes that include numerous speciﬁc medications. When medication classes were dominated by one speciﬁc medication (>80%), we report the
numbers for the speciﬁc medication rather than the class and perform subsequent
analyses at the speciﬁc medication level. Abbreviations: ACEI, angiotensinconverting enzyme inhibitor; ARB, angiotensin receptor blocker; CVD, cardiovascular disease; GI, gastrointestinal; NSAID, nonsteroidal anti-inﬂammatory
drugs; PPI, proton pump inhibitors; SNRI, serotonin norepinephrine reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor; US-VMP, United States
Veteran Microbiome Project.

3.1.3. The gut microbiota α-diversity metrics were correlated with numerous
health conditions and medications
We also examined α-diversity of the gut microbiota taxa (Appendix C;
Table C2). Most of the correlates of α-diversity showed an inverse relationship, including CVD (P ¼ 0.04), PVD (P ¼ 0.04), trazadone
(P ¼ 0.04), and albuterol (P ¼ 0.02). However, this was not always the
case; other supplemental vitamins (P ¼ 0.03) (including all vitamins
except for Vitamin D) and other CVD medications/supplements
(P ¼ 0.03) (e.g., aspirin, ﬁsh oil, etc.) were associated with higher
α-diversity.

predictors. In the PERMANOVA analysis, race (P ¼ 0.01), homeless frequency (P ¼ 0.02), and bipolar disorders (P ¼ 0.03) were correlated with
weighted UniFrac; age (P ¼ 0.02), bipolar disorders (P ¼ 0.04), gastroenteritis (P ¼ 0.03), CVD (P ¼ 0.047), PVD (P ¼ 0.02), BDI (P ¼ 0.04),
and psychiatric medications (P ¼ 0.01) were most correlated with unweighted UniFrac (Fig. 2).
In the stepwise constrained ordination analysis, data were examined
for both unweighted and weighted UniFrac in four groups: 1) demographics; 2) health conditions and metrics; 3) medication classes; and,
4) speciﬁc medications. In the demographics group, we found that age
(P ¼ 0.01) correlated most strongly with the unweighted UniFrac distance metric (Table 3, Fig. 3A). Race (P ¼ 0.01) and sex (P ¼ 0.002)

4. Discussion
In this study of Veterans with military-related exposures and associated health conditions, we found a number of associations with the microbial taxonomic composition of the gut, including bipolar disorders,
severe depressive symptoms based on the BDI, PVD, gastroenteritis,
opioid and stimulant use disorders, beta-blockers, SNRI antidepressants,
diabetes medications, and GI medications including PPIs, and omeprazole, which is a speciﬁc type of PPI. Gut microbiota functional composition was associated with overall perceived physical health (SF-36 PCS),
CHF, use of muscle relaxers, omeprazole, and supplemental vitamin use.
Military service-related characteristics and conditions, such as
5
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Fig. 1. Correlation heat map of the associations between medications and health conditions and metrics. Prescription medications are
shown on the y-axis, and health conditions and
metrics are on the x-axis. The color indicates the
strength of correlation with positive values
shown in purple and negative values shown in
red. Abbreviations: ACEI/ARB, angiotensinconverting enzyme inhibitor/angiotensin II receptor blocker; BDI, Beck Depression Inventory;
BP, blood pressure; CVD, cardiovascular disease;
GI, gastrointestinal; NSAIDs, nonsteroidal antiinﬂammatory drugs; PCS, Physical Health Composite Score; PPI, proton pump inhibitors; Psyc,
psychiatric; SF-36, 36-Item Short Form Health
Survey; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. (For interpretation of the
references to color in this ﬁgure legend, the
reader is referred to the Web version of this
article.)

bipolar disorders, but this is somewhat difﬁcult to interpret as this is a
very common member of the human gut microbiota with wide-ranging
correlations. Some prior studies separated bipolar disorders into the
clinical subtypes of I and II (Coello et al., 2019; Evans et al., 2017; Aizawa
et al., 2016), or differentiated bipolar individuals based on severity of
current symptoms (Painold et al., 2019) or pharmacological intervention
(Flowers et al., 2017, 2019), which we did not. Additionally, we found
decreased Ruminococcus 1 in participants that suffered from severe
depressive symptoms based on the BDI. One study that recruited 115
participants experiencing bipolar disorders reported a lower abundance
of the family Ruminococcaceae compared to control participants (Evans
et al., 2017), though the consistency of this result is difﬁcult to assess as
this is a broad and diverse family.
We showed an increase in Blautia genus of the Firmicutes phylum in
individuals with anxiety disorders as determined by the SCID-5-I/P W/
PSY SCREEN (First et al., 2016). Gacias et al. showed that Blautia was
associated with increases in anxiety-like behavior (social avoidance) in
mice (Gacias et al., 2016). Blautia has also been correlated with obesity
and type 2 diabetes. (Ozato et al., 2019; Egshatyan et al., 2015). However, other work has suggested that Blautia may have protective effects in
some contexts (Wong et al., 2016; Jenq et al., 2015), and a recent study
found an inverse association in men between Blautia abundance and
anxiety (Taylor et al., 2019) measured by the Depression, Anxiety, and

deployment history, combat exposure, PTSD, and number of TBIs, were
not among the strongest correlates of overall gut microbiota metrics, such
as α- or β-diversity. However, there were several notable differences in
taxonomic relative abundance associated with deployments, as well as
with many of the health-related metrics and disorders that are highly
prevalent among Veterans, including insomnia, bipolar and anxiety disorders, and depressive symptoms.
We observed that age, race, and sex correlated with the gut microbiota composition, as has been observed in many other population
studies, including the Human Microbiome Project (Jackson et al., 2018;
Falony et al., 2016; Human Microbiome Project, 2012). Mental health
conditions were highly prevalent among the US-VMP cohort, and we
found that bipolar disorders were associated with bacterial community
structure. Previous ﬁndings on the community composition of the gut
microbiota and bipolar disorders are mixed, with some showing community level differences in individuals with bipolar disorders (Coello
et al., 2019; Evans et al., 2017) and others ﬁnding no such differences
(Vinberg et al., 2019; Hu et al., 2019; Painold et al., 2019). There were
many taxonomic differences cited by previous studies associated with
bipolar disorders, speciﬁcally, increased Actinobacteria (Painold et al.,
2019), increased Flavonifractor (Coello et al., 2019), and inconsistent
associations with Faecalibacterium (Coello et al., 2019; Evans et al.,
2017). Our study found that Bacteroides was increased in individuals with
6
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exposure to traumatic stressors and subsequent diagnoses of mental
health conditions (e.g., PTSD) to the development of future physical
health conditions (e.g., CVD) (Dyball et al., 2019). Increased permeability of the GI lumen, commonly referred to as “leaky gut”, which also
has been shown to lead to exaggerated inﬂammation (Camilleri, 2019),
has been identiﬁed in those suffering from affective, GI (e.g., inﬂammatory bowel disorders [IBD]), and cardiovascular disorders (Ait-Belgnaoui et al., 2012; Bischoff et al., 2014; Novakovic et al., 2020).
Similarly, it is common for those GI and cardiovascular disorders to have
comorbid affective disorders (Wilmes et al., 2021; Cohen et al., 2015).
Given the high rates of inﬂammatory disorders among Veterans (Tanielian et al., 2008; Breland et al., 2017), this is an important population
within which to study the microbiota-gut-brain axis and physical and
mental health. We predeominantly focused on lifetime diagnoses of
mental health conditions because we were not adequately powered to
examine current mental health conditions, or to compare short-term
versus long-term conditions. However, this is an important area for
future research, as there is some evidence that prolonged exposure to
mental health conditions can lead to enhanced immunological and inﬂammatory changes (Dickerson et al., 2016; Goldsmith et al., 2016).
Number of deployments showed a positive relationship with Prevotella 6 and Collinsella and a negative relationship with Biﬁdobacterium.
A deployment is a temporary relocation of a military service member,
typically to an international location, and can vary in length from three to
ﬁfteen months and does not necessarily include combat. Relocation
inherently involves the exposure to different environmental microbes
(Barberan et al., 2015), changes in diet (Turnbaugh et al., 2009b), novel
living quarters (Lax et al., 2014), and novel cohabitants (Song et al.,
2013), all of which have been shown to inﬂuence the gut microbiome.
Prevotella is a highly diverse genus with numerous clades, many of which
are typically underrepresented in Westernized countries (Tett et al.,
2019). Veterans with multiple deployments may have increased exposure
to these types of microbes that are less common among Western populations, which could explain this ﬁnding. Collinsella has been associated
with low dietary ﬁber intake and high circulating insulin (Gomez-Arango
et al., 2018). There is high prevalence of insulin resistance and diabetes
among Veterans (Liu et al., 2017), and the US-VMP cohort generally has a
homogeneous, Western-style diet, low in dietary ﬁber, and high in animal
foods, reﬁned carbohydrates, and added sugars (Flowers et al., 2017). A
reduction in dietary ﬁber intake could result in a general switch in the gut
away from short-chain fatty acid (SCFA) production and toward more
lactate fermentation processes (Pylkas et al., 2005). Biﬁdobacterium has
many known probiotic strains and has been largely considered a genus
comprised of beneﬁcial microbes (Azad et al., 2018). Biﬁdobacterium
species are generally known for their ability to catabolize complex carbohydrates and produce the necessary substrates for the Bif Shunt
metabolic pathway (O'Callaghan and van Sinderen, 2016). The Bif Shunt
pathway breaks down phosphates to generate adenosine triphosphate
(ATP) and produces SCFAs as end products (O'Callaghan and van Sinderen, 2016). SCFAs are important signaling molecules, and they can
inﬂuence systemic inﬂammation by reducing inﬂammatory cytokines
such as interleukin (IL)-6 and tumor necrosis factor alpha (TNF-⍺) and
increasing anti-inﬂammatory cytokines such as IL-10 (Vinolo et al.,
2011). However, they have also been associated with obesity and may
reﬂect an increased capacity to harvest energy from food (Gentile and
Weir, 2018).
Our results show that the most common medications among Veterans
in the US-VMP were comparable to adults in the US as a whole, antidepressants and CVD-related medications, including lipid-lowering medications, beta-blockers, and ACEIs (Hales et al., 2019). The prevalence of
antidepressants and other mental health medication prescriptions was
higher in the US-VMP than in the US generally, which is likely due to
recruitment of Veterans that were actively seeking healthcare from a
VHA medical center. It is important to note that some of the commonly
prescribed medications in this cohort were classiﬁed as treatment for a
speciﬁc condition based on the classiﬁcation system from Epocrates,

Fig. 2. The variables most correlated with the gut microbial community
composition. Bar graph showing univariate associations between demographics, health conditions/metrics and medications and the gut microbiota
community composition, as quantiﬁed by weighted (light grey) and unweighted
(black) UniFrac β-diversity indices. The variables shown had the highest levels
of correlation with β-diversity determined by PERMANOVA across all of the
examined variables, all with P < 0.1; asterisks represent variables showing
nominally signiﬁcant associations with P < 0.05. Abbreviatons: BDI, Beck
Depression Inventory; PERMANOVA, permutational analysis of variance.

Table 3
The subsets of variables demonstrating the strongest correlation with the gut
microbial community composition.
Distance metric

Exposure

Variable

P

Unweighted
UniFrac

Demographics

Age

0.014

Health conditions/
metrics

PVD

0.018

Bipolar disorders
Stimulant use disorder
Gastroenteritis
Severe depressive
symptoms (BDI)
Beta blockers
SNRI antidepressants
Diabetes medications
Sex

0.038
0.046
0.050
0.050

Race
Stimulant use disorder

0.012
0.022

Bipolar disorders
Opioid use disorder
Other GI medications
PPIs
Omeprazole

0.028
0.046
0.010
0.050
0.032

Medication class

Weighted
UniFrac

Demographics

Health conditions/
metrics

Medication class
Speciﬁc medications

0.008
0.014
0.028
0.002

Footnote. Microbial composition as measured by unweighted and weighted
UniFrac distance metrics. The exposures were grouped into four categories: 1)
demographics; 2) health conditions and metrics; 3) medication classes; and 4)
speciﬁc medications. P-values were generated by a stepwise contrained ordination model. Abbreviations: BDI, Beck Depression Inventory; GI, gastrointestinal;
PPI, proton pump inhibitor; PVD; peripheral vascular disease; SNRI, serotonin
and norepinephrine reuptake inhibitor.

Stress Scale (Lovibond and Lovibond, 1995) – although this was a pilot
study, and the ﬁndings could be spurious due to the large number of
comparisons made.
Many of the physical and mental health conditions correlated with
the gut microbiota in this study, such as gastroenteritis, CVD, anxiety
disorders, and affective disorders, have been associated with underlying
inﬂammation (Dickerson et al., 2016; Goldsmith et al., 2016; Vivinus-Nebot et al., 2014; Namazi et al., 2018; Hamjane et al., 2020). It is
also worth noting that among military Veterans there is evidence linking
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Fig. 3. Biplots of the strongest correlates of the
gut microbial community composition. These
biplots show the results of the analysis described in
Table 3 with each dot representing a gut microbiota
sample from one individual. Dots that cluster together
have more similar gut microbiota composition with
arrows pointing in a similar direction characterized by
similar types of microbiota. The gut microbiota
composition was quantiﬁed based on a) unweighted
and b) weighted UniFrac distance metrics. The
strength of correlations between variables and the gut
microbial community composition was determined by
a stepwise contrained ordination model. The arrows
represent the direction and strength of association
with the strongest correlates of these measures of
composition in terms of: 1) phylum-level taxonomy;
2) demographics; 3) health conditions and metrics;
and 4) medication classes and speciﬁc medications
(shown in blue). Unweighted UniFrac did not show
any statistically signiﬁcant correlation with speciﬁc
medications. Abbreviations: BDI, Beck Depression Inventory; GI, gastrointestinal; MDS, multidimensional
scaling; PPI, proton pump inhibitor; PVD, peripheral
vascular disease; SNRI, serotonin and norepinephrine
reuptake inhibitor. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)

gut pH, which alters the types of microbes that can survive and grow
(Duncan et al., 2009). This ﬁnding is consistent with prior literature
showing that these commonly prescribed medications are associated
with alterations in the gut microbiota, such as lower microbial diversity
and increases in potentially commensal microbes, speciﬁcally the genera
of Enterococcus, Streptococcus, Staphylococcus, and the potentially pathogenic species Escherichia coli. We likewise saw an association between
increased Streptococcus and PPIs (Imhann et al., 2016; Jackson et al.,
2016). These alterations in the gut microbiota composition are likely not
entirely benign, as use of PPIs is also associated with an increased risk of
enteric infections, including C. difﬁcile (Janarthanan et al., 2012), which
carries a high mortality risk (Oake et al., 2010) and is known to respond
well to restoration of a healthy microbiota composition through fecal
microbiota transplant therapy (Youngster et al., 2014). Moreover, these

(Epocrates) but that in this population, it is likely that certain medications were being used off-label to address other conditions (Leslie et al.,
2009). For example, 18% of the cohort was prescribed “seizure medications,” but drugs within this class of neurological medications (e.g.,
gabapentin) are often used in the VHA at a lower dosage as mood stabilizers or for pain control (Ketter et al., 2003). Another example is
prazosin, which in Fig. 1 was classiﬁed as a blood pressure lowering
medication, but is frequently used among Veterans to treat PTSD-related
nightmares (Raskind et al., 2018).
We found that PPIs, particularly omeprazole, as well as other GI
medications (which included digestive enzymes and heart burn medications, most commonly ranitidine) showed a strong correlation with
overall gut microbiota composition and functional pathways. This is not
surprising, as these medications target the gut function. PPIs increase the
8
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Fig. 4. Taxonomic differences based
on characteristics of US-VMP Veterans. These plots show the taxa that
differed signiﬁcantly (FDR < 0.05) with
demographics, health conditions and
metrics, medication classes, and speciﬁc
medications. The color shows whether
there is a direct (red) or inverse (blue)
relationship between the exposure and
taxonomic relative abundance determined by ANCOM. Abbreviations:
ANCOM, analysis of composition of
microbiomes; BDI, Beck Depression Inventory; FDR, false discovery rate; SNRI,
serotonin and norepinephrine reuptake
inhibitor; UCG, unclassiﬁed genus. (For
interpretation of the references to color
in this ﬁgure legend, the reader is
referred to the Web version of this
article.)

dependent on interactions with the gut microbiota. This is thought to be
the case with metformin, the most frequently prescribed medication for
type 2 diabetes (Vallianou et al., 2019). Our results conﬁrm those of
other studies that diabetes medications are associated with alterations in
the overall gut microbiota (Jackson et al., 2018; Vallianou et al., 2019).
This study has some notable limitations and strengths. The participants were mainly recruited through the VA medical facilities in Eastern
Colorado, and do not fully represent the Veteran population as a whole,
particularly younger, healthier Veterans who are less likely to regularly
use VA health services. Fecal samples were collected in-person for some
of the participants, while other participants collected samples at home
and shipped the samples to the study center. Sample transit time (time
between when the sample was collected and when the sample was placed
into an ultra-low temperature freezer at the research facility) was variable and conditions before and during shipment may have varied among
samples. We tried to address this issue using previously applied
deblooming methods, but it is likely impossible to fully correct for this
issue. The samples were sequenced based on the 16S rRNA gene, which
limits our ability to accurately classify species-level taxonomy or to understand gut microbiota functions. We examined gut microbiota functional pathways that were inferred from taxonomy, but these analyses are
preliminary in nature since microbiota functions would be more accurately assessed through shotgun metagenomic sequencing of samples,
which we hope to do in the future. A record of a medication prescription
in the VA EMR is indicative of a provider order, but it does not necessarily
mean the Veteran has taken the medication. However, medication
adherence levels tend to be better among those getting care at the VA
than outside the VA (Gaffney et al., 2020). The medications recorded in
the VA EMR may underestimate the true prevalence of medication use
among these individuals since Veterans may get some of their medications outside the VA, particularly for medications that are available
over-the-counter, such as those for heartburn. It is difﬁcult to isolate the
effects of medication from the effects of health conditions, and medications may have interaction effects, which are difﬁcult to estimate without
larger sample sizes. It is also inherently challenging to classify medications into their predominant therapeutic indications, as numerous medications can be used to treat different conditions (Raskind et al., 2018).
We chose to use Epocrates classiﬁcation system, which is one of the most
commonly used sources of drug information by physicians that does not
require a subscription (Apidi et al., 2017). This study has unique
strengths as well, including the validated measures of health conditions
and substance use disorders and the comprehensive information about

Table 4
Variables most correlated with the gut microbiota functional pathways
inferred using PiCrust2.
Distance
metric

Exposure

Variable

P

Jaccard

Demographics
Health conditions/
metrics
Medication classes
Speciﬁc medications
Demographics

Sex
Congestive heart failure

0.002
0.026

Muscle relaxers
Omeprazole
Sex
Race
SF-36 PCS

0.008
0.016
0.002
0.038
0.022

Other supplemental
vitamins
Omeprazole

0.002

Bray-Curtis

Health conditions/
metrics
Medication classes
Speciﬁc medications

0.006

Footnote. β-diversity metrics Jaccard and Bray-Curtis were utilized with PiCrust2
to infer functional pathways most correlated to variables. Variables were
grouped into four categories: 1) demographics; 2) health conditions; 3) medication classes; and, 4) speciﬁc medications. Abbreviations: PiCrust2, Phylogentic
investigation of Communities by reconstruction of unobserved states v2; SF-36
PCS, 36-Item Short Form Health Survey Physical Health Composite Score.

ﬁndings are particulary relevant in light of recent wide-spread PPI
de-implementation strategies, based on ﬁndings suggesting that many
PPI prescriptions are inappropriate (Orelio et al., 2021).
In some cases, it was difﬁcult to isolate whether a condition or its
treatment was more strongly associated with the gut microbiota. For
example, we saw that PVD, SNRIs, and beta-blockers were associated
with differences in the gut microbiota composition. There were only nine
individuals with PVD in the cohort; almost half of them were on betablockers, and one-third were on SNRIs, making it difﬁcult to tease
apart these effects. This is an important area for further research as PVD
showed some of the most pervasive associations with gut microbiota
characteristics, including with ⍺-diversity, overall gut microbiota community composition and relative abundance of Faecalibacterium. In a
recent study of atherosclerotic CVD, disease status was more strongly
associated with the gut microbiota than CVD medication (Jie et al.,
2017). However, the relationships among disease, medications, and the
gut microbiota are complex, and the efﬁcacy of some medications may be
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Fig. 5. Biplots of the strongest correlates of the
gut microbial functional pathways. These biplots
show the results of the same analysis as shown in
Table 4 with each dot representing a gut microbiota
sample from one individual. Dots that cluster together
have more similar gut microbiota functional pathways
with arrows pointing in a similar direction characterized by similar functions. The gut microbiota
functional pathways were quantiﬁed based on: a)
Jaccard and b) Bray-Curtis distance metrics. The
strength of correlations between variables and the
functional pathways was determined by a stepwise
constrained ordination model. The arrows represent
the direction and strength of association with the
strongest correlates of these measures of composition
in terms of: 1) functional pathways; 2) demographics;
3) health conditions and metrics; and 4) medication
classes and speciﬁc medications (shown in blue).
Functional pathway labels and pathway details can be
found in Appendix C; Table C1. Abbreviations: CHF,
congestive heart failure; SF-36 PCS, 36-Item Short
Form Health Survey Physical Health Composite Score.
(For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web
version of this article.)

medical conditions and medications available through the VA EMRs. As
the recruited population in the US-VMP increases over time, we will be
better powered to more thoroughly characterize the associations between individual characteristics (i.e., current vs lifetime psychological
conditions) and the gut microbiota of US Veterans.

consider in microbiome studies, and it adds to the growing body of
literature supporting associations between gut microbiota features and
numerous health conditions, particularly those that tend to be characterized by underlying inﬂammation, such as gastroenteritis and affective
disorders.

5. Conclusions

Data availability

In this study, we leveraged the extensive information collected in the
VA EMR in order to examine the relationships of the gut microbiota to
demographic factors, common health-related conditions, militaryspeciﬁc exposures, and medications. This work will help to inform decisions about which types of information are important to collect and

The VHA has rules about data security that aim to protect the privacy
of Veteran health information. Thus, the personal health data used for
this study cannot be made publicly available. Please contact the authors
for further information or collaboration.
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Appendix A

Table A.1
International Classiﬁcation of Diseases, Ninth and Tenth Revision (ICD-9 and ICD-10) codes for health conditions
Health condition

ICD-9 code

ICD-10 code

Cancer

140-165, 170–195, 200–208, 230.3, 230.4, 231.2, 233.0, 233.2, 233.4, 233.6,
273.0, 273.3, V10.05, V10.06, V10.11, V10.3, V10.42, V10.46

Congestive heart
failure (CHF)
Peripheral vascular
disease (PVD)

398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.13, 404.91, 404.93, 425,
428, 429.3
093.0, 437.3, 440–442, 443.1, 443.2, 443.8, 443.9, 447.1, 557.1, 557.9,
785.4, V43.4

C00–C26, C30–C34, C37–C41, C43, C45–C58, C60–C76, C81–C86, C88,
C90–C96, D01.0, D01.1, D01.2, D02.2, D03, D05, D07.0, D07.5, D45,
D47.Z9, D89.0, Z85.038, Z85.048, Z85.118, Z85.3, Z85.42, Z85.46
A18.84, I09.81, I11.0, I13.0, I13.2, I42, I43, I50, I51.7

Cardiovascular
disease (CVD)
Diabetes

362.34, 430–438, 781.4, 784.3, 997.0, 410, 412

Liver disease
Renal disease

Chronic pulmonary
disease (CPD)
Gastroenteritis

415.0, 416.8, 416.9, 490–496, 500–505, 506.4, 508.1, 508.8

A52.01, E08.51, E08.52, E09.51, E09.52, E10.51, E10.52, E11.51, E11.52,
E13.51, E13.52, I67.0, I67.1, I70–I72, I73.01, I73.1, I73.8, I73.9, I77.1,
I77.71, I77.72, I77.73, I77.74, I77.79, 179, I96, K55.1, K55.8, K55.9,
Z95.820, Z95.828
G03.8, G45, G46, G97.0, G97.2, G97.3, G97.8, H34.0, I60–I63, I65–I69,
I97.81, I97.82, R295, R47.01, I21, I22, I25.2
E11.65, E13.2, E13.31, E13.32, E13.33, E13.34, E13.351, E13.359,
E13.36, E13.39, E13.4, E13.5, E13.610, E13.65, E13.69, E13.8, E13.9
K7030, K74.0, K74.60, K74.69, K72.90, K76.7, K65.2, R18.0, R18.8,
I85.01, I85.11, I85.10
A18.11, A52.75, B52.0, D30.0, D41.0, D41.1, D41.2, D59.3, E08.2, E09.2,
E74.8, I12.0, I13.11, M10.3, N00–N04, N05.2. N05.3, N05.4, NO5.5,
N05.9, N06.2, N06.3, N06.4, N06.5, N07.2, N07.3, N07.4, N07.5, N08,
N13.1, N13.2, N13.3, N17–N19, N25, N26.1, N26.9, Q61.02, Q61.1Q61.5, Q61.8, Q62.0-Q62.3, R94.4, Z48.22, Z49, Z91.15, Z94.0, Z99.2
J47, J60-J67, J68.4, J70.1-J70.4, J70.8

558, 558.1, 558.3, 558.41

K52, K52.0, K52.2, K52.21, K52.22, K52.29, K52.81, K52.9, A09

249, 250, 357.2, 362.01, 362.02, 362.03, 362.04, 362.05, 362.06, 366.41
571.2, 571.5, 572.2, 572.4, 567.23, 589.5, 589.51, 589.59, 456.0, 456.2,
456.20, 456.21
016.0, 095.4, 223.0, 236.91, 271.4, 274.10, 283.11, 403.01, 403.11, 403.91,
404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 580–582, 583.1, 583.2,
583.4, 583.6, 583.7, 584–588, 591, 753.12–753.17, 753.19, 753.2, 794.4,
V42.0, V45.1, V56

Footnote: CHF, congestive heart failure; ICD, International Classiﬁcation of Diseases; PVD, peripheral vascular disease; CVD, cardiovascular disease; CPD, chronic
pulmonary disease.

Appendix B. Supplemental Methods
Bloom analysis for US Veteran Microbiome Project (VMP)
Our sampling procedures allowed participants to provide samples in one of two ways: 1) participants could provide samples during their in-person
visit; or 2) participants could take a sampling kit to their home to collect their sample and ship the sample back to the research facility. Although the
participants were provided with an ice pack and instructed to ship the sample back to the research facility with the ice pack, adherence to this protocol
was not always followed. Therefore, samples shipped back to the research facility had the potential to be above freezing temperature for extended
periods of time. In contrast, samples collected by participants that elected to provide their sample during the in-person visit were immediately frozen
and stored at 80  C.
Amir et al. were the ﬁrst to report on the phenomena of “blooming”, where certain taxa that are not obligate anerobic bacteria can bloom in fecal
samples if not quickly refrigerated or frozen (Amir et al., 2017b). Their publication provided detailed explanations, ﬁles, and code to remove taxa that
had been determined to have artiﬁcially “bloomed” in the American Gut Project data. We followed these methods to perform debloooming of our data. A
total of N ¼ 95 samples was provided during in-person visits, whereas a total of N ¼ 236 samples were shipped. The R2 values from constrained analysis
of principal coordinates of the weighted UniFrac distance matrix were used as a means to objectively determine how deblooming analysis impacted
measures of bacterial community structure. We examined R2 values of both the dichotomous variable of shipped (yes, N ¼ 236; no, N ¼ 95) and the
continuous variable of transit days (number of days between when the sample was collected by the participant and when the sample was placed into the
80  C freezer at the research facility; mean  SD (2.94  3.82 days)). We performed this analysis on the data before deblooming analysis, after
deblooming analysis of all samples (N ¼ 331), and after deblooming analysis of only samples shipped back to the research facility (N ¼ 236). The results
of this analysis are shown in Figure B1.
The R2 values from the constrained analysis of principal coordinates is a measure of the variance explained by the factor “shipping” or “transit time”
on the bacterial community composition. Ideally, after deblooming, these variables would no longer explain any variation in the gut microbiota
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composition (i.e., R2 ¼ 0). While this was not the case, the R2 values were substantially reduced by performing the deblooming analysis on only samples
shipped back to the research facility relative to no deblooming or deblooming all samples, supporting that this method helped to correct for the effects of
sample transit conditions.
Additionally, Bokulich et al. showed that the taxa that artiﬁcially bloom in fecal samples exposed to room temperature conditions for extended
periods of time are overrepresented by members of the Enterobacteriaceae family (Bokulich et al., 2019). For this reason, we also examined all the
sub-operational taxonomic unit (sOTUs) in our dataset belonging to the Enterobacteriaceae family for signiﬁcant correlation with transit days to ensure
that our initial deblooming analysis did not overlook other taxa that may have bloomed. We found 21 sOTUs in our dataset belonging to the
Enterobacteriaceae family. The results for the correlations run for each sOTU against transit days can be found in Supplemental Table B1.
There was only 1 sOTU from the Enterobacteriaceae family that was signiﬁcantly correlated with transit days (sOTU:
4c8288bfbd76958c0c094d87b97650f8; Genus: Escherichia-Shigella; Species: Unknown). This sOTU was also identiﬁed by Amir et al. (Amir et al.,
2017b) and therefore was already removed from the dataset during the initial deblooming analysis. Consequently, in this report we have used data
derived from deblooming of only the samples shipped back to the research facility.

Figure B.1. Bar plots of the R2 values from constrained analysis of principal coordinates of the weighted UniFrac distance matrix for the shipped samples. The analysis
was performed on the data before deblooming analysis, after deblooming analysis on all samples, and after deblooming analysis on only samples shipped to the
research facility.

Table B.1
Table of correlation results of sOTUs belonging to the family of Enterobacteriaceae against transit days.
Taxonomy
sOTU
03156252fe6d4e8f09aeafc3bef8622f
054e27bdfbc9ec73099088c1ad200dfc
1aed9737c554992f5e99137008f672b0
26d8f09d7fc0ca9b34c16f29516675b8
2c9ba6e5f77c3128bab581f724f48d26
3bef2d36c2b2da1c7ca58212c72a9864
411bb521b1feec2b25d0128518f057bb
4c8288bfbd76958c0c094d87b97650f8
57f3e001eec8fb0909c4ea3524aa27eb
583cc45144c321d815f2d4d90a55f4f8
64ee8ff8e0185065c7d02eb2488d90aa
83182c1c91133da26653aeb58052e7cc
9a5171a5b50ffc0b6b48abc366e0076b
aa1e3f1e251b633baa135e028732abc3
bad443c798b38eed5f2008d150376715
be011200bb48abc86a552828c40c6c8c
bf8b84f3b4506cf8bed2c2b22fddb848
c0a0588789c30c5f413216dfef6cc8f0
e42382ea3fa1149094d507e3167e462b
ec9ed9b5acb1ccd3cdfd196b3632904c
fc5860decf6565201a343d865b30951f

Genus
Enterobacter
Providencia
Citrobacter
Rahnella
Morganella
Proteus
Escherichia-Shigella
Escherichia-Shigella
Citrobacter
Klebsiella
Morganella
Raoultella
Klebsiella
Enterobacter
Unclassiﬁed
Cronobacter
Hafnia-Obesumbacterium
Morganella
Rosenbergiella
Unclassiﬁed
Serratia

Correlation results
Species
Providencia vermicola
uncultured
uncultured
ASC10
Escherichia coli Nissle 1917

uncultured
BAB-5304
Oxytoca KA-2
mixed culture X17-21
Sakazakii
Bta3-1

Pantoea agglomerans

12

R-values
0.058
0.03
0.056
0.0095
0.021
0.016
0.068
0.17
0.093
0.035
0.021
0.03
0.017
0.0091
0.043
0.039
0.0092
0.049
0.0084
0.021
0.069

p -value
0.29
0.59
0.31
0.86
0.7
0.78
0.22
0.0014
0.092
0.52
0.7
0.59
0.75
0.87
0.44
0.48
0.87
0.37
0.88
0.71
0.21

Signiﬁcance

**
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Appendix C. Supplemental tables
Table C.1
Functional pathway labels and pathway details from Fig. 5.
Pathway label

Pathway details/webpage link

GLYOXDEG
GLYCOL-TCA-GLYOX-BYPASS
P105
1269
2942
5345
5918
6737
7392
4FS-7
REDCITCYC
COMPLETE-ARO
FASYN-ELONG
NAGLIPASYN
PHOSLIPSYN
UDPNAGSYN

Superpathway of glycol metabolism and degradation
Superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass
TCA cycle IV (2-oxoglutarate decarboxylase)
CMP-3-deoxy-D-manno-octulosonate biosynthesis
L-lysine biosynthesis III
Superpathway of L-methionine biosynthesis (by sulfhydrylation)
Superpathway of heme b biosynthesis from glutamate
Starch degradation V
Taxadiene biosynthesis (engineered)
Phosphatidylglycerol biosynthesis I (plastidic)
TCA cycle VI (Helicobacter)
Superpathway of aromatic amino acid biosynthesis
Fatty acid elongation – saturated
Lipid IVA biosynthesis (E. coli)
Superpathway of phospholipid biosynthesis I (bacteria)
UDP-N-acetyl-D-glucosamine biosynthesis I

Table C.2
Model selection results for linear regressions of α-diversity. Three measures of α-diversity (Observed species, Shannon diversity, and Faith's Phylogenetic Diversity (PD))
were modeled as a function of predictors from four groups of exposures: 1) demographics; 2) health conditions and metrics; 3) medication classes; and 4) speciﬁc
medications. The regression effect estimates (beta) and 95% conﬁdence interval (CI) are shown for the selected predictors that are statistically signiﬁcant. Most of the
diseases and medications showing a signiﬁcant association with α-diversity show an inverse relationship, but there are some exceptions. For example, vitamins and
“other CVD medications,” which includes aspirin and ﬁsh oil, are associated with higher α-diversity. The beta estimates correspond to 1 standard deviation change in
each metric of α-diversity.
Predictor group

α-diversity metric

Selected covariates

Demographics

Observed species
Shannon
Faith's PD
Observed species

Non-signiﬁcant: Race
Non-signiﬁcant: Race
Non-signiﬁcant: Race
CVD
¡0.5
(-0.98, -0.01)
0.046
Non-signiﬁcant: BMI, Bipolar disorders, Severe depressive symptoms (BDI), Gastroenteritis, Cannabis use disorder
PVD
¡0.7
(-1.36, -0.04)
0.039
Non-signiﬁcant: BMI, Bipolar disorders, Severe depressive symptoms (BDI), Gastroenteritis, Cannabis use disorder
CVD
¡0.531
(-1.03, -0.03)
0.039
Non-signiﬁcant: BMI, Bipolar disorders, Severe depressive symptoms (BDI), SF-36 PCS, Cancer, PVD, Gastroenteritis, Cannabis
use disorder
Other Vitamins
0.37
(0.05, 0.71)
0.028
Non-signiﬁcant: Antithrombotics, Beta blockers, Other CVD medications, Diabetes medications, Bronchodilators, NSAIDs,
SSRIs, Other Psychiatric medications, Sexual function medications, Vitamin D
Bronchodilators
¡0.34
(-0.65, -0.02)
0.036
Other supplemental vitamins
0.38
(0.05, 0.71)
0.025
Non-signiﬁcant: Antithrombotics, Other CVD medications, Seizure medications, Other Psychiatric medications, Sexual
function medications, Vitamin D
Other CVD medications
0.38
(0.03, 0.73)
0.031
Non-signiﬁcant: Antithrombotics, Beta blockers, Bronchodilators, Non-opioid analgesics, NSAIDs, SSRIs, Other psychiatric
medications, Sexual function medications, Other supplemental vitamins, Vitamin D
Trazadone
¡0.35
(-0.68, -0.02)
0.038
Non-signiﬁcant: Albuterol, Bupropion, Sildenaﬁl, Cholecalciferol
Albuterol
¡0.44
(-0.81, -0.07)
0.021
Non-signiﬁcant: Bupropion, Trazadone, Sildenaﬁl, Cholecalciferol
Non-signiﬁcant: Bupropion, Trazadone, Sildenaﬁl, Cholecalciferol

Health conditions & metrics

Shannon
Faith's PD

Medication classes

Observed species

Shannon

Faith's PD

Speciﬁc medications

Observed species
Shannon
Faith's PD

Estimate

95% CI

P

Footnote. Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index; CVD, cardiovascular disease, NSAIDs, nonsteroidal anti-inﬂammatory drugs; SF-36
PCS, 36-Item Short Form Health Survey Physical Health Composite Score; PD, phylogenetic diversity; PVD, peripheral vascular disease; SSRI, selective serotonin reuptake inhibitor.
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